Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Comparative Analysis of IPSS, IPSS-R, and WPSS for Predicting Survival and Leukemic Transformation in Myelodysplastic Neoplasms: A Real-World Single-Center Experience.

View Full Paper
Ask AI
Bookmark
Share

Authors

MLMihai-Emilian LapadatOSOana StancaNBNicoleta Berbec

Discussion

Loading...

Member takes

Overview

Retrospective analysis found IPSS-R significantly predicts survival in MDS patients, highlighting its clinical utility.

Key Points

  • IPSS-R was identified as a strong independent predictor for overall survival and progression-free survival.
  • Patients reclassified as lower-risk by IPSS-R had a median OS of 67.5 months, a significant survival improvement.
  • Leukemic transformation rates were significantly lower in reclassified lower-risk patients than in higher-risk patients.
  • The analysis involved a cohort of 117 MDS patients treated between 2018 and 2022 at a single center.

Cite This Study

Lapadat et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64784f43https://doi.org/10.3390/jcm14165757
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic impact of pre-transplant IPSS-m risk downstaging in Myelodysplastic Syndromes2025
  2. 2IPSS-m outperforms IPSS-R in younger adults with Myelodysplastic Syndromes: A retrospective age-stratified analysis2025
  3. 3Integrated machine learning-based prognostic models for patients with Myelodysplastic Syndromes/neoplasms (MDS)2025
  4. 4Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R2025 · 1 citations
  5. 5Comparative evaluation of ipss-m and cpss-mol in CMML: Impact of molecular markers on prognosis2025